Stoke's Q2 Update: Faster Phase 3, Bigger Bet on a 2027 Readout

Phase 3 timelines have tightened around the 2027 data readout

Stoke has moved the key catalyst closer. In January, it accelerated timelines to complete 150-patient enrollment in Q2 2026 and pointed to a mid-2027 Phase 3 data readout. The later June update is more definitive: Stoke has now completed enrollment of 162 patients, expects a Phase 3 data readout in the third quarter of 2027, and plans to initiate a rolling U.S. NDA submission in the first quarter of 2027. For a pre-revenue biotech, that turns the next milestone into a clearer countdown.

The tighter schedule raises both upside and execution risk

That timeline matters because Stoke is building its near-term narrative around zorevunersen as a first-in-class potential disease-modifying treatment for Dravet syndrome. If the program works, a Q3 2027 readout could do more than produce a positive top-line result; it could materially change how investors value the company.

The trade-off is that a faster schedule leaves less room for delay. Because Stoke still needs efficacy proof and has no approved product, the compressed timeline increases the importance of execution. This now looks less like an open-ended development story and more like a catalyst-driven setup leading into 2027.

Long-term open-label data are giving bulls more to point to

The timeline update is the headline, but the other reason investors remain interested is the growing body of long-term signal. Stoke's open-label data show durable seizure reductions, statistically significant annual improvements in Vineland-3 cognition and behavior scores through four years, and no new safety findings after more than 930 doses.

That matters because it is not only a single short-term endpoint. Multi-year follow-up suggests the signal may reflect real biology rather than a transient effect, which is especially important for a program marketed around disease modification.

The data support Stoke's RNA-based disease-modifying narrative

Stoke was founded around RNA-based medicines that aim to restore protein expression, and the 4-year open-label data are framed as supporting disease-modifying potential. That does not prove disease modification, but it does give bulls a coherent mechanism and clinical rationale to watch.

Cash position and market size keep the setup alive

Dravet syndrome is a small market, but Stoke's own estimate suggests a meaningful opportunity: approximately 16,000 U.S. patients, with about 6,000 patients under age 25 viewed as immediately addressable. That is niche, but not trivial, for a first-in-class program.

Financially, Stoke still appears able to wait for the next proof point. The latest update shows a net loss of -$0.79 per share versus a consensus estimate of -$0.8435, even with no revenue for the quarter. Separately, cash and marketable securities totaled $354.3 million, with pro forma cash around $420 million after raising $65.7 million net through its ATM program. That runway matters because it reduces near-term financing pressure ahead of the Phase 3 readout.

What the market is still pricing into STOK

This is still a clock-driven stock. Earlier material pointed to completion of enrollment in Q2 2026 and a mid-2027 data readout; the cleaner current reference is the June filing: 162 patients enrolled, with a Phase 3 data readout anticipated in the third quarter of 2027. The update does not change the thesis. It narrows the window.

The Q1 results help explain why speculative support has held. Stoke reported a net loss of -$0.79 per share versus a consensus estimate of -$0.8435, despite no revenue for the quarter, and the stock rose 1.22% in after-hours trading. That suggests investors are still paying for an intact path to the next catalyst rather than for current earnings.

Key support points and key risks

What keeps the bullish case alive - The loss beat and lack of revenue reflect a pre-revenue development stage, not a new commercial problem. - The Phase 3 program still shows no treatment discontinuations to date. - The long-term safety signal remains clean, with no new safety findings after more than 930 doses.

What could break it - Any new safety signal would hit sentiment quickly, even after an extended period without new findings. - A negative or ambiguous Phase 3 readout would challenge the core thesis. - Any further drift away from the current 2027 timeline would likely hurt credibility as much as it would extend the waiting period.